Glenmark Life Sciences Limited IPO (Glenmark Life Sciences IPO) Detail - Ajay Singh Chauhan

Glenmark Life Sciences Limited IPO (Glenmark Life Sciences IPO) Detail

Incorporated in 2011, Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The agency develops, manufactures, and materials terrific APIs for cardiovascular ailment (CVS), valuable nervous machine ailment (CNS), pain control, and diabetes, gastrointestinal issues, anti-infectives, and different therapeutic areas. It in addition operates in Contract Development and manufacturing operations (CDMO) to offer services to distinctiveness Pharmaceutical businesses.

Its merchandise are being bought in India and also expoted to multiple countries i.E. Europe, North America, Latin America, Japan, and so on. Currently, it has four production centers at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an combination annual hooked up ability of 725.8 KL as of December 31, 2020.

Competitive strengths

Leading manufacturer of selected specialized APIs for continual healing regions like CVS, CNS, diabetes, and pain control.
Export merchandise in Europe, Latin America, North America, Japan, and the relaxation of the world.
Strong courting with main international widely wide-spread agencies.
Proven music document of strong financial performance.
High-first-class product production with R&D infrastructure.

Objects of the Issue
To make payment of outstanding buy consideration to the promoter for the spin-off of the API business from the promoter into the employer.
To finance capital expenditure requirements.
To meet widespread company purposes.

Company Financials:

ParticularsFor the year/period ended (₹ in million)
31-Mar-2131-Mar-2031-Mar-19
Total Assets19,970.7517,256.0414,753.95
Total Revenue18,859.7615,493.038,868.65
Profit After Tax3,515.813,130.981,955.92

Glenmark Life Sciences IPO Details

IPO Opening DateJul 27, 2021
IPO Closing DateJul 29, 2021
Issue TypeBook Built Issue IPO
Face Value₹2 per equity share
IPO Price₹695 to ₹720 per equity share
Market Lot20 Shares
Min Order Quantity20 Shares
Listing AtBSE, NSE
Issue Size[.] Eq Shares of ₹2
(aggregating up to ₹1,513.60 Cr)
Fresh Issue[.] Eq Shares of ₹2
(aggregating up to ₹1,060.00 Cr)
Offer for Sale6,300,000 Eq Shares of ₹2
(aggregating up to ₹453.60 Cr)

Glenmark Life Sciences IPO Tentative Timetable

The Glenmark Life Sciences IPO open date is Jul 27, 2021, and the close date is Jul 29, 2021. The issue may list on Aug 6, 2021.

IPO Open DateJul 27, 2021
IPO Close DateJul 29, 2021
Basis of Allotment DateAug 3, 2021
Initiation of RefundsAug 4, 2021
Credit of Shares to Demat AccountAug 5, 2021
IPO Listing DateAug 6, 2021

Glenmark Life Sciences IPO Lot Size

The Glenmark Life Sciences IPO market lot size is 20 shares. A retail-individual investor can apply for up to 13 lots (260 shares or ₹187,200).

ApplicationLotsSharesAmount (Cut-off)
Minimum120₹14,400
Maximum13260₹187,200

Glenmark Life Sciences IPO Promoter Holding

Pre Issue Share Holding100%
Post Issue Share Holding82.84%

Company Contact Information

Glenmark Life Sciences Limited
Plot No. 170-172, Chandramouli Industrial Estate,
Mohol Bazarpeth, Solapur 413 213,


Phone: +91 2189 234456/ +91 2189
Email: [email protected]

Websitehttp://www.glenmarklifesciences.com/

Leave a Reply

Your email address will not be published. Required fields are marked *